Editas Medicine, Inc. (EDIT)

NMS – Real vaqt narxi. Valyuta: USD

2.93

-0.13 (-4.25%)

Yopilishda: May 12, 2026, 4:00 PM EDT

2.92

-0.01 (-0.22%)

Bozordan keyin: May 12, 2026, 7:15 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Editas Medicine, Inc. (EDIT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Editas Medicine, Inc. (EDIT)

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Videolar

No Data

Press-relizlar

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Genflow Biosciences PLC Announces Directorate Change

Search stocks

Editas Medicine, Inc. (EDIT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Editas Medicine, Inc. (EDIT)

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Videolar

No Data

Press-relizlar

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Genflow Biosciences PLC Announces Directorate Change